Indivior Pharmaceuticals, Inc. is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The firm provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. The company sells its products in the United States and in other selected areas of the world.
¿Cuál es el ratio P/E de Indivior Pharmaceuticals, Inc (INDV)?
El ratio P/E de Indivior Pharmaceuticals, Inc es 23.5368
¿Quién es el CEO de Indivior Pharmaceuticals, Inc?
Mr. Joseph Ciaffoni es el Chief Executive Officer de Indivior Pharmaceuticals, Inc, se unió a la empresa desde 2024.
¿Qué tal es el rendimiento del precio de la acción INDV?
El precio actual de INDV es de $37.09, ha disminuido un 0.74% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Indivior Pharmaceuticals, Inc?
Indivior Pharmaceuticals, Inc pertenece a la industria Pharmaceuticals y el sector es Health Care
¿Cuál es la capitalización bursátil de Indivior Pharmaceuticals, Inc?
La capitalización bursátil actual de Indivior Pharmaceuticals, Inc es $4.4B
¿Es Indivior Pharmaceuticals, Inc una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 8 analistas han realizado calificaciones de análisis para Indivior Pharmaceuticals, Inc, incluyendo 4 fuerte compra, 8 compra, 1 mantener, 0 venta, y 4 fuerte venta